Onconova Therapeutics Inc.

224 articles about Onconova Therapeutics Inc.

• Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

  5/25/2023

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first participant has been dosed in an investigator-sponsored Phase 2 trial of oral rigosertib plus the PD-1 inhibitor pembrolizumab in patients with metastatic melanoma who have progressed on prior PD-1/L1 inhibitor therapy.

• Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

  5/15/2023

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced financial results for the three months ended March 31, 2023, and provided a business update.

• Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

  5/12/2023

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”) today announced that Steven M. Fruchtman, M.D., President & CEO of Onconova Therapeutics, will participate in a Ladenburg Thalmann virtual R&D showcase on Thursday, May 18, 2023, at 11:00 a.m. ET.

• Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

  5/11/2023

  Onconova Therapeutics, Inc. today announced that the first patient has been dosed in the Company’s Phase 1/2a trial evaluating narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC).

• Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium

  5/8/2023

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”) today announced an upcoming presentation at the International Society of Investigative Dermatology (ISID) International Epidermolysis Bullosa Symposium, which is being held in Osaka, Japan through May 9, 2023.

• Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

  5/4/2023

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its first quarter 2023 financial results on Monday, May 15, 2023.

• Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting

  4/19/2023

  Onconova Therapeutics, Inc. today announced new preclinical data on narazaciclib in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting.

• Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

  4/6/2023

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that its Chief Medical Officer (CMO) Mark Gelder, M.D., recently passed away unexpectedly.

• Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib

  3/23/2023

  Onconova Therapeutics, Inc. and Pangea Biomed, a company combining machine learning and deep RNA analysis to expand access to precision oncology, today announced a research collaboration between the companies.

• Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

  3/16/2023

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the twelve months ended December 31, 2022, and provided a business update.

• Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting

  3/15/2023

  Onconova Therapeutics, Inc. today announced the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 – 19, 2023.

• Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

  3/9/2023

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023.

• Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib’s Mechanisms of Action at the AACR Targeting RAS Conference

  3/7/2023

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”) announced new preclinical data characterizing rigosertib’s mechanisms of action in a poster at the American Association for Cancer Research Special Conference on Targeting RAS (AACR Targeting RAS Conference).

• Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

  2/7/2023

  Onconova Therapeutics, Inc. today announced that the second of two evaluable participants in an investigator-initiated Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC) achieved a complete response of all cancerous skin lesions following 4 treatment cycles and remains on oral rigosertib.

• Onconova Therapeutics to Present at the 2023 Guggenheim Oncology Conference

  2/1/2023

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the 2023 Guggenheim Oncology Conference taking place February 8-9, 2023 in New York City.

• Onconova Therapeutics Announces Participation in the Channelchek Takeaway Series

  1/26/2023

  Onconova Therapeutics, Inc. today announced their participation in the Channelchek Takeaway Series from the J.P.Morgan Healthcare Conference, to be broadcast Thursday, January 26, starting at 10:00 EST.

• Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors

  12/19/2022

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the appointments of Peter Atadja, Ph.D., and Trafford Clarke, Ph.D., as independent members of the Company’s Board of Directors.

• Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference

  12/7/2022

  Onconova Therapeutics, Inc. today announced that it will participate in the MedInvest Oncology Investor Conference being held in New York, NY on December 14-15, 2022.

• Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference

  11/28/2022

  Onconova Therapeutics, Inc. today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022.

• Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update

  11/14/2022

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced plans for a Phase 1/2a trial of narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer.